UroGen Pharma Ltd.
URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase IIIā¦ read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$45.00
Price+2.71%
$1.18
1Y
Price
Market Cap
$2.192b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-5.2%
EBITDA Margin-19.8%
Net Profit Margin-45.6%
Free Cash Flow Margin-5.2%
EBITDA Margin-19.8%
Net Profit Margin-45.6%
Free Cash Flow MarginRevenue
$188.734m
+71.9%
1y CAGR+34.2%
3y CAGR+32.8%
5y CAGREarnings
-$97.636m
+36.4%
1y CAGR-2.9%
3y CAGR-0.5%
5y CAGREPS
-$1.98
+37.9%
1y CAGR+15.6%
3y CAGR+18.2%
5y CAGRBook Value
-$132.396m
$252.590m
Assets$384.986m
Liabilities$196.128m
DebtDebt to Assets
77.7%
-2.8x
Debt to EBITDAFree Cash Flow
-$159.135m
+2.2%
1y CAGR-30.7%
3y CAGR-19.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company